ENGN Stock Summary and Trading Ideas (Engene Therapeutics | NASDAQ:ENGN)

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Engene Therapeutics trades on the NASDAQ stock market under the symbol ENGN.

As of June 5, 2026, ENGN stock price declined to $1.64 with 950,625 million shares trading.

ENGN has a beta of 0.26, meaning it tends to be less sensitive to market movements. ENGN has a correlation of 0.00 to the broad based SPY ETF.

ENGN has a market cap of $109.85 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that ENGN belongs to (by Net Assets): BBC.

ENGN has underperformed the market in the last year with a price return of -57.2% while the SPY ETF gained +25.0%. ENGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -83.2% and -5.2%, respectively, while the SPY returned +7.9% and -0.7%, respectively.

ENGN support price is $1.61 and resistance is $1.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENGN shares will trade within this expected range on the day.